HDAC (Histone Deacetylases) are a group of enzymes that allow histones to more tightly wrap the DNA by removing acetyl groups (O=C-CH3) from -N-acetyl lysine amino acids. This is significant because DNA is wrapped around histones and that acetylation and de-acetylation control how DNA is expressed. In contrast to histone acetyltransferase, it acts differently. Since non-histone proteins are also among their targets, HDAC proteins are now also referred to as lysine deacetylases (KDAC) in order to better reflect their mode of action. The histone deacetylases are members of the ancient protein superfamily known as the histone deacetylase superfamily, along with the acetylpolyamine amidohydrolases and the acetoin utilization proteins.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V41465 | 4-iodo-SAHA | 1219807-87-0 | 4-Iodo-SAHA (1k) is a class I and class II histone deacetylase (HDAC) inhibitor (antagonist) with EC50s of 1.1, 0.95, 0.12, 0.24, and 0.85 for Skbr3, HT29, U937, JA16, and HL60 cells, respectively. |
|
V0282 | Abexinostat (PCI24781; CRA024781) | 783355-60-2 | Abexinostat (formerly PCI-24781; CRA-024781) is a novel, potent and hydroxamic acid-based pan-HDAC (histone deacetylase) inhibitor with potential anticancer activity. |
|
V2907 | ACY-738 | 1375465-91-0 | ACY-738 (ACY738) is a novel, potent, selective, brain penetrable and orally-bioavailable HDAC6 inhibitor with neuroprotective and anticancer activities. |
|
V78075 | Antitumor agent-123 | Antitumor agent-123 (Copmound 4d) effectively inhibits multiple kinase targets with anti-cancer effects such as JAK2, JAK3, HDAC1 and HDAC6, with IC50s of 34.6 and 2.6 μM for JAK2 and JAK3, respectively. | |
|
V0283 | AR-42 (HDAC-42, NSC-736012, OSU-42) | 935881-37-1 | AR-42 (HDAC-42, NSC-736012, OSU-42 etc.) is a novel and potent histone deacetylase (HDAC) inhibitor with potential antitumor activity. At 30 nM, its IC50 inhibits HDAC. |
|
V0260 | Belinostat (PXD101; PX105684; NSC726630) | 414864-00-9 | Belinostat (formerly PXD-101; PX-105684; NSC-726630; trade name Beleodaq) is a novel, potent and selective HDAC (histone deacetylase) inhibitor with high anticancer activity. |
|
V0262 | BG45 | 926259-99-6 | BG45 (BG-45) is a novel, potent and selective class I HDAC inhibitor with potential anticancer activity. |
|
V78544 | BRD 4354 ditrifluoroacetate | BRD 4354 (ditrifluoroacetate) is an inhibitor (blocker/antagonist) of HDAC5 and HDAC9, with IC50s of 0.85 and 1.88 μM respectively. | |
|
V16989 | BRD3308 | 1550053-02-5 | BRD3308 is a selective HDAC3 inhibitor (antagonist) with IC50 of 54 nM. |
|
V0263 | BRD73954 | 1440209-96-0 | BRD73954 (BRD-73954) is a novel, potent and dual inhibitor of histone deacetylase 6 (HDAC6) and HDAC8 with potential anticancer activity. |
|
V0267 | CAY10603 | 1045792-66-2 | CAY10603 is a novel, potent and selective HDAC6 (Histone deacetylase) inhibitor with potential anticancer activity and a potential to treatneurodegenerative diseases. |
|
V2867 | CAY10683 (Santacruzamate A) | 1477949-42-0 | Santacruzamate A (also known as CAY10683) is a potent and selective inhibitor of HDAC (histone deacetylase) with IC50 of 119 pM for HDAC2, it exhibits >3600-fold selectivity over other HDACs. |
|
V0277 | CUDC-101 | 1012054-59-9 | CUDC-101 is a novel, potent and multi-targeted histone deacetylase (HDAC) inhibitor with potential anticancer activity. |
|
V0280 | Dacinostat (LAQ-824; NVP-LAQ-824) | 404951-53-7 | Dacinostat (formerly LAQ824; NVP-LAQ824) is a novel, potent and hydroxamate-based inhibitor of histone deacetylase (HDAC) with potential anticancer activity. |
|
V0264 | Domatinostat (4SC202) | 910462-43-0 | Domatinostat (formerly 4SC-202)is a novel, potent, and orally bioavailable benzamide-based Class I HDAC inhibitor with potential anticancer activity. |
|
V3847 | Domatinostat HCl | Domatinostat HCl (formerly 4SC202; 4SC-202), the hydrochloride salt ofDomatinostat, is a class I HDAC inhibitor (HDACi) with potential anticancer activity. | |
|
V3848 | domatinostat tosylate | 1186222-89-8 | Domatinostat (formerly known as 4SC-202) is a novel class I HDAC inhibitor (HDACi) that potently inhibited survival and proliferation of primary human colon cancer cells and established CRC lines (HT-29, HCT-116, HT-15, and DLD-1). |
|
V0290 | Droxinostat (NS41080) | 99873-43-5 | Droxinostat(formerly NS-41080) is a novel, potent, selective inhibitor of histone deacetylase (HDAC) with potential anticancer activity. |
|
V50034 | Elevenostat | 1454902-97-6 | Elevenostat (JB3-22) is a selective HDAC11 inhibitor (IC50=0.235 µM). |
|
V0256 | Entinostat (MS275; SNDX275) | 209783-80-2 | Entinostat (formerly known as MS-275; SNDX-275) is a potent, benzamide-based and class-selective but generally pan-HDAC (histone deacetylase) inhibitor with potential anticancer activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
